Na grande maioria dos casos, a doença da altitude aguda, o edema pulmonar por grande altitude (EPGA) e o edema cerebral por grande altitude (ECGA) podem ser evitados subindo-se lentamente acima das altitudes >2500 m. Uma vez acima dos 3.000 m, a altitude em que se dorme não deve aumentar mais que 500 m em 24 horas. Além disso, um dia de repouso deve ser feito a cada 3-4 dias.[29]Luks AM, Auerbach PS, Freer L, et al. Wilderness medical society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. Wilderness Environ Med. 2019 Dec;30(4s):S3-18.
https://www.wemjournal.org/article/S1080-6032(19)30090-0/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31248818?tool=bestpractice.com
Em pacientes com propensão à doença da altitude aguda (DAA) ou que pretendem subir rapidamente, é possível administrar acetazolamida ou dexametasona de forma profilática.[37]Basnyat B, Gertsch JH, Holck PS, et al. Acetazolamide 125mg BD is not significantly different from 37mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) TRIAL. High Alt Med Biol Spr. 2006 Spring;7(1):17-27.
http://www.ncbi.nlm.nih.gov/pubmed/16544963?tool=bestpractice.com
[38]Dumont L, Mardirosoff C, Tramèr MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ. Jul 29;321(7256):267-72.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC27441
http://www.ncbi.nlm.nih.gov/pubmed/10915127?tool=bestpractice.com
[39]Williamson J, Oakeshott P, Dallimore J. Altitude sickness and acetazolamide. BMJ. 2018 May 31;361:k2153.
http://www.ncbi.nlm.nih.gov/pubmed/29853484?tool=bestpractice.com
A acetazolamida é preferida, mas, caso o paciente seja intolerante ou alérgico, poderá ser administrada dexametasona.[29]Luks AM, Auerbach PS, Freer L, et al. Wilderness medical society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. Wilderness Environ Med. 2019 Dec;30(4s):S3-18.
https://www.wemjournal.org/article/S1080-6032(19)30090-0/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31248818?tool=bestpractice.com
[40]Donegani E, Paal P, Küpper T, et al. Drug use and misuse in the mountains: a UIAA MedCom consensus guide for medical professionals. High Alt Med Biol. 2016 Sep;17(3):157-84.
http://www.ncbi.nlm.nih.gov/pubmed/27583821?tool=bestpractice.com
[41]Nieto Estrada VH, Molano Franco D, Medina RD, et al. Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs. Cochrane Database Syst Rev. 2017 Jun 27;6:CD009761.
https://doi.org/10.1002/14651858.CD009761.pub2
http://www.ncbi.nlm.nih.gov/pubmed/28653390?tool=bestpractice.com
Revisões sistemáticas para avaliar a eficácia de medicamentos profiláticos usados com menos frequência (por exemplo, agonistas seletivos do receptor de serotonina, antagonistas do receptor N-metil-D-aspartato, antagonistas do receptor de endotelina 1, anticonvulsivantes e espironolactona), e intervenções variadas ou não farmacológicas (incluindo ginkgo biloba), não conseguiram determinar a eficácia ou segurança, devido ao pequeno número de estudos disponíveis e sua qualidade limitada.[29]Luks AM, Auerbach PS, Freer L, et al. Wilderness medical society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. Wilderness Environ Med. 2019 Dec;30(4s):S3-18.
https://www.wemjournal.org/article/S1080-6032(19)30090-0/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31248818?tool=bestpractice.com
[42]Gonzalez Garay A, Molano Franco D, Nieto Estrada VH, et al. Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs. Cochrane Database Syst Rev. 2018 Mar 12;3:CD012983.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012983/full
http://www.ncbi.nlm.nih.gov/pubmed/29529715?tool=bestpractice.com
[43]Molano Franco D, Nieto Estrada VH, Gonzalez Garay AG, et al. Interventions for preventing high altitude illness: Part 3. Miscellaneous and non-pharmacological interventions. Cochrane Database Syst Rev. 2019 Apr 23;4:CD013315.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013315/full
http://www.ncbi.nlm.nih.gov/pubmed/31012483?tool=bestpractice.com
[44]Tsai TY, Wang SH, Lee YK, et al. Ginkgo biloba extract for prevention of acute mountain sickness: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2018 Aug 17;8(8):e022005.
https://bmjopen.bmj.com/content/8/8/e022005.long
http://www.ncbi.nlm.nih.gov/pubmed/30121603?tool=bestpractice.com
Foi demonstrado que o nifedipino reduziu a incidência de EPGA em pessoas com história pregressa de EPGA documentado radiograficamente.[45]Bärtsch P, Maggiorini M, Ritter M, et al. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med. 1991 Oct 31;325(18):1284-9.
http://www.nejm.org/doi/full/10.1056/NEJM199110313251805#t=article
http://www.ncbi.nlm.nih.gov/pubmed/1922223?tool=bestpractice.com
Os indivíduos com doenças existentes devem consultar um médico para discutir o planejamento pré-viagem, para reduzir o risco de doença relacionada a grandes altitudes. As discussões devem avaliar se as condições são estáveis, se são necessários ajustes na dosagem e se o destino tem recursos médicos disponíveis.[1]Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 4: environmental hazards & risks - high elevation travel & altitude illness. May 2023 [internet publication].
https://wwwnc.cdc.gov/travel/yellowbook/2024/environmental-hazards-risks/high-elevation-travel-and-altitude-illness
[6]Luks AM, Hackett PH. Medical conditions and high-altitude travel. N Engl J Med. 2022 Jan 27;386(4):364-73.
http://www.ncbi.nlm.nih.gov/pubmed/35081281?tool=bestpractice.com